Literature DB >> 2885336

Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.

H Tamaki, N Amino, M Aozasa, M Mori, O Tanizawa, K Miyai.   

Abstract

Thyroid-stimulating antibody (TSAb) and TSH binding inhibitor immunoglobulin (TBII) were measured serially in 10 patients with Graves' disease at the time of postpartum onset (n = 2) or relapse (n = 8) of Graves' thyrotoxicosis and in 5 patients with Graves' disease who were in remission and had no postpartum relapse of Graves' thyrotoxicosis. TSAb was measured by a sensitive cAMP accumulation assay using FRTL-5 cells, and TBII was determined by radioreceptor assay. In no patient with either recurrent or new onset postpartum hyperthyroidism did the serum free T3 index (FT3I) rise before the free T4 index (FT4I). Of the 10 patients who had postpartum thyrotoxicosis, concomitant increases in serum FT4I and FT3I, and TSAb and TBII were observed in only 1 patient. Increases in TSAb and TBII after those in FT4I and FT3I occurred in 6 patients. In 1 patient, an increase in TBII was associated with the occurrence of thyrotoxicosis, but TSAb increased 1 month later. In the other 2 patients, a TSAb increase was followed by the development of thyrotoxicosis, but TBII increased later. In 3 of these 10 patients, the increased serum FT4I and FT3I values decreased spontaneously, whereas the TSAb and TBII levels increased continuously. No positive test or increase in TSAb or TBII was found in the 5 patients with Graves' disease who did not have a postpartum relapse of thyrotoxicosis. These data indicate that postpartum initiation of Graves' thyrotoxicosis is not always associated with an increase in circulating anti-TSH receptor antibodies and that such parameters are poor indicators of thyroid function. Intrathyroidal humoral or cell-mediated immunological mechanisms may also be involved in mediating thyrotoxicosis in Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885336     DOI: 10.1210/jcem-65-2-324

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Autoimmune thyroid disease and pregnancy.

Authors:  N Amino; H Tada; Y Hidaka
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

2.  Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients.

Authors:  K Kazuo; T Fujikado; G Ohmi; J Hosohata; Y Tano
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 3.  Immunity to the thyroid-stimulating hormone receptor.

Authors:  J Furmaniak; B R Smith
Journal:  Springer Semin Immunopathol       Date:  1993

4.  Improvement of infiltrative ophthalmopathy in parallel with decrease of thyroid-stimulating antibody (TSAb) activity in two patients with hypothyroid Graves' disease.

Authors:  H Tamaki; N Amino; Y Iwatani; K Miyai
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

Review 5.  Thyroid autoimmunity and female gender.

Authors:  L Chiovato; P Lapi; E Fiore; M Tonacchera; A Pinchera
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

6.  Thyroid autoimmunity in pregnant Nigerians.

Authors:  Oluwatosin O Kayode; Ifedayo A Odeniyi; Sandra Iwuala; Oluwarotimi B Olopade; Olufemi A Fasanmade; Augustine E Ohwovoriole
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

7.  Comparative frequency of four different types of pregnancy-associated thyrotoxicosis in a single thyroid centre.

Authors:  Akane Ide; Nobuyuki Amino; Takumi Kudo; Waka Yoshioka; Mako Hisakado; Eijun Nishihara; Mitsuru Ito; Shuji Fukata; Hirotoshi Nakamura; Akira Miyauchi
Journal:  Thyroid Res       Date:  2017-08-08

8.  Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance.

Authors:  Francis S Balucan; Syed A Morshed; Terry F Davies
Journal:  J Thyroid Res       Date:  2013-04-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.